Vogt, currently president of Millipore's BioPharmaceutical division, will be leaving Millipore on 27 May 'to pursue other interests', according to the company. No successor has been named, suggesting that the departure was something of a surprise, and Millipore CEO Martin Madaus will lead the division until a successor is named.
Cambrex has named David DeMarco to the position of vice president, strategic planning. DeMarco will direct the development and implementation of the company's transformational business strategy as Cambrex moves into the specialty therapeutics market.
Drug delivery company Nektar Therapeutics has appointed Joseph Krivulka to its board of directors. Krivulka, currently the founder and president of Triax Pharmaceuticals, will replace Melvin Perelman, who has retired from Nektar's board after almost 10 years of service.
VaxGen, a US company developing vaccines for smallpox, anthrax and HIV, has boosted its QA/QC functions with the appointment of Henk Kocken as vice president, quality systems. Kocken, who has more than 20 years of experience in the pharmaceutical, biotechnology and diagnostics industries, will report directly to Carmen Betancourt, senior vice president, regulatory affairs and quality systems.
Akubio, a specialist in acoustic biosensor technology, has appointed Jerry Walker, formerly European president of GE Healthcare Discovery Systems, as its new CEO. Meanwhile, Jonathan Glenn, formerly global head of finance at Celltech, becomes Akubio's chief financial officer.